Order Article Reprints

Kushiya H, Hiraoka K, Suzuki T, Inoko K, Inagaki A, Niwa H, Sasaki K, Nakamura T, Tsuchikawa T, Shichinohe T, et al. Retroviral Replicating Vector Toca 511 (Vocimagene Amiretrorepvec) for Prodrug Activator Gene Therapy of Lung Cancer. Cancers. 2022; 14(23):5820. https://doi.org/10.3390/cancers14235820

Kushiya, Hiroki, Kei Hiraoka, Tomohiro Suzuki, Kazuho Inoko, Akihito Inagaki, Hiroki Niwa, Katsunori Sasaki, Toru Nakamura, Takahiro Tsuchikawa, Toshiaki Shichinohe, and et al. 2022. "Retroviral Replicating Vector Toca 511 (Vocimagene Amiretrorepvec) for Prodrug Activator Gene Therapy of Lung Cancer" Cancers 14, no. 23: 5820. https://doi.org/10.3390/cancers14235820

Kushiya, H., Hiraoka, K., Suzuki, T., Inoko, K., Inagaki, A., Niwa, H., Sasaki, K., Nakamura, T., Tsuchikawa, T., Shichinohe, T., Jolly, D. J., Kasahara, N., & Hirano, S. (2022). Retroviral Replicating Vector Toca 511 (Vocimagene Amiretrorepvec) for Prodrug Activator Gene Therapy of Lung Cancer. Cancers, 14(23), 5820. https://doi.org/10.3390/cancers14235820